ATBECHDEDKESFRGBGRITLILUNLSEMCPTIESILTLVFIROMKCYALTRBGCZEEHUPLSK..HRIS..MTNORS..SM..................J0009290-CORR013581206CORRECTED EUROPEAN PATENT SPECIFICATIONB8B120250219W172deBibliographieenBibliographyfrBibliographieEP19173675.0201110202020061720201103enenen40576710 P20101022US201161445785 P20110223US2025021920250820191218201951202412252024522024071920250219202508A61K 47/68 20170101AFI20240213BHEP A61K 31/498 20060101ALI20240213BHEP A61K 31/519 20060101ALI20240213BHEP A61K 31/4745 20060101ALI20240213BHEP A61K 31/5377 20060101ALI20240213BHEP A61K 31/4375 20060101ALI20240213BHEP A61K 31/436 20060101ALI20240213BHEP A61K 45/06 20060101ALI20240213BHEP A61P 35/00 20060101ALI20240213BHEP A61P 35/02 20060101ALI20240213BHEP A61K 45/06 20130101 LI20130101BHEP A61K 47/6849 20170801 LI20170802BHEP A61K 47/6867 20170801 LI20170802BHEP A61K 31/436 20130101 LI20130808BHEP A61K 31/4375 20130101 LI20130808BHEP A61K 31/4745 20130101 LI20130808BHEP A61K 31/498 20130101 LI20130808BHEP A61K 31/519 20130101 LI20130808BHEP A61K 31/5377 20130101 LI20130808BHEP A61K 47/6811 20170801 FI20190212BHEP A61P 35/00 20180101 LI20200327BHEP A61P 35/02 20180101 LI20200327BHEP A61P 43/00 20180101 LI20200331BHEP deSYNERGIEWIRKUNG ZWISCHEN AURISTATIN-BASIERTEN ANTIKÖRPER-WIRKSTOFFKONJUGATEN UND HEMMERN DES PI3K-AKT-MTOR-WEGSenSYNERGISTIC EFFECTS BETWEEN AURISTATIN-BASED ANTIBODY DRUG CONJUGATES AND INHIBITORS OF THE PI3K-AKT MTOR PATHWAYfrEFFETS SYNERGIQUES ENTRE DES CONJUGUÉS D'ANTICORPS ET DE MÉDICAMENT À BASE D'AURISTATINE ET DES INHIBITEURS DE LA VOIE PI3K-AKT-MTORWO-A1-2009/048967WO-A1-2009/117531MCEARCHERN ET AL.: "Activity of SGN-35 in Preclinical Models of Combination Therapy and Relapse Prevention", HAEMATOLOGICA, THE HEMATOLOGY JOURNAL, vol. 95, no. S4, 31 October 2010 (2010-10-31), XP002731348, Retrieved from the Internet <URL:http://www.haematologica.org/content/haematol/95/supplement_4/S1.full.pdf> [retrieved on 20141002]CHESON B D: "Novel therapies for peripheral T-cell non-Hodgkin's lymphomas", CURRENT OPINION IN HEMATOLOGY, RAPID SCIENCE PUBLISHERS, PHILADELPHIA, PA, US, vol. 16, no. 4, 1 July 2009 (2009-07-01), pages 299 - 305, XP008172491, ISSN: 1065-6251, DOI: 10.1097/MOH.0B013E32832AD69APATRICK B. JOHNSTON ET AL: "A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma", AMERICAN JOURNAL OF HEMATOLOGY, vol. 85, no. 5, 1 January 2010 (2010-01-01), pages NA - NA, XP055123462, ISSN: 0361-8609, DOI: 10.1002/ajh.21664YOUNES ET AL: "Multiple complete responses in a phase 1 dose-escalation study of the antibody- drug conjugate SGN-35 in patients with relapsed or refractory CD30-positive lymphomas", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 112, no. 11, 1 January 2008 (2008-01-01), pages 1006, XP008170898, ISSN: 0006-4971JONA A ET AL: "Novel treatment strategies for patients with relapsed classical Hodgkin lymphoma", BLOOD REVIEWS, CHURCHILL LIVINGSTONE, AMSTERDAM, NL, vol. 24, no. 6, 15 September 2010 (2010-09-15), pages 233 - 238, XP027471337, ISSN: 0268-960X, [retrieved on 20101101], DOI: 10.1016/J.BLRE.2010.08.003T.S. LEWIS ET AL.: "Auristatin-based antibody-drug conjugates are synergistic in combination with PI3K-AKT-mTOR pathway inhibitors in hematologic malignancies and carcinoma", CANCER RESEARCH, vol. 71, no. S1, 15 April 2011 (2011-04-15), XP002731350, Retrieved from the Internet <URL:http://cancerres.aacrjournals.org/cgi/content/short/71/8_MeetingAbstracts/1789> [retrieved on 20141001]11835158.4262980120111020LEWIS, Timothy S.Bothell, WA Washington 98021USLAW, Che-LeungBothell, WA Washington 98021USMCEARCHERN, Julie A.Bothell, WA Washington 98021USSeagen Inc.101874460P021717EP1 PMC21823 30th Drive S.E.Bothell, WA 98021USAbel & Imray LLP101670696Westpoint Building James Street WestBath BA1 2DAGBALATBEBGCHCYCZDEDKEEESFIFRGBGRHRHUIEISITLILTLULVMCMKMTNLNOPLPTRORSSESISKSMTR